Emerging targeted therapies for breast cancer

被引：2
作者：
Arnedos, Monica
Seidman, Andrew D.
机构：
[1] Royal Marsden Hosp, Dept Med, Breast Unit, London SW3 6JJ, England
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Canc Med Serv, New York, NY 10021 USA
[3] Cornell Univ, Joan & Sanford I Weill Sch Med, Ithaca, NY USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2007年 / 21卷 / 02期
关键词：
D O I：
10.1016/j.hoc.2007.03.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Breast cancer is the most common neoplasia among women in the world. For the last few years there has been an increasing interest in the development of agents against molecular targets considered to be involved in the process of malignant transformation or tumor progression. Experimental data indicate that various intracellular signaling pathways may be activated or overexpressed in patients who have breast cancer. Targeted therapies against these pathways have recently become one of the most active and promising areas of development in oncology.
引用
收藏
页码：321 / +
页数：21
相关论文
共 82 条
[1]   Overview of tyrosine kinase inhibitors in clinical breast cancer [J].
Agrawal, A ;
Gutteridge, E ;
Gee, JMW ;
Nicholson, RI ;
Robertson, JFR .
ENDOCRINE-RELATED CANCER, 2005, 12 :S135-S144
[2]  
Albain K, 2002, BREAST CANCER RES TR, V76, pS33
[3]   Depletion of p185(erbB2), Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity [J].
An, WG ;
Schnur, RC ;
Neckers, L ;
Blagosklonny, MV .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (01) :60-64
[4]   ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression [J].
Anderson, NG ;
Ahmad, T ;
Chan, K ;
Dobson, R ;
Bundred, NJ .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) :774-782
[5]  
[Anonymous], P AM SOC CLIN ONCOL
[6]   Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer [J].
Baselga, J ;
Albanell, J ;
Ruiz, A ;
Lluch, A ;
Gascón, P ;
Guillém, V ;
González, S ;
Sauleda, S ;
Marimón, I ;
Tabernero, JM ;
Koehler, MT ;
Rojo, F .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5323-5333
[7]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[8]  
BASELGA J, 2005, P AM SOC CLIN ONC, V23
[9]  
BASELGA J, 2004, P AM SOC CLIN ONC, V22
[10]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
123456789